

**Drug Utilization Review Board Meeting  
Agenda, Open Session July 21, 2021  
10:00 a.m. – 2:00 p.m.**

**Meeting Location\***

\*Due to COVID-19, this meeting will be held virtually. Please use the information below to join the meeting:

**Public/Participant Line: Dial: (312) 626-6799, Meeting ID: 871 4397 3724**

**Zoom Meeting: <https://us02web.zoom.us/j/87143973724>, Passcode: 254284**

Members of the general public are required to complete a conflict of interest form if they intend to provide public comments to the Board. To assist the operator in coordinating public comment, completed forms are due 1 week prior to the meeting (July 14, 2021). Please email the completed form to [Annette.Grant@ks.gov](mailto:Annette.Grant@ks.gov).

**Board Members**

Moneeshindra Mittal, MD  
James Backes, PharmD  
Jennifer Clair, MD  
Gregory Burger, PharmD, CPPS, FASHP, EMT

Michele Reisinger, DNP, APRN, FNP-BC  
Arthur Snow, MD  
Kristen Powell, PharmD

**KDHE-DHCF Staff**

Annette Grant, RPh  
Victor Nguyen, PharmD

Carol Arace, Administrative Specialist

**Gainwell Technologies/KEPRO Staff**

Karen Kluczykowski, RPh  
Kathy Kaesewurm, RN, BSN

Christina Faulkner, PharmD, BCPS  
Harry Vu, PharmD

**MCO Staff**

Mark DeMary, PharmD, **Aetna Better Health of Kansas**  
Angie Yoo, PharmD, **Sunflower State Health Plan**  
Sunny Bounyalath, PharmD, **UnitedHealthcare Community Plan**

## **I. CALL TO ORDER**

### **A. Announcements**

This meeting will be operator-assisted. An opportunity for public comment was given at the top of the agenda.

## **II. OLD BUSINESS**

### **A. Review and Approval of April 21, 2021 Meeting Minutes**

## **III. NEW BUSINESS**

### **A. Mental Health Medication Advisory Committee (MHMAC)**

#### **1. ADHD Medications – Safe Use for All Ages**

At the May 2021 MHMAC meeting, the committee revised the ADHD Medications – Safe Use for All Ages criteria to include Evekeo® ODT, Qelbree®, and Azstarys™ and updates to the dosing limits table. Step therapy for Qelbree® was also reviewed.

- i. Prior Authorization Criteria
- ii. \*Public Comment
- iii. Board Discussion

#### **2. Antidepressant Medications – Safe Use for All Ages**

At the May 2021 MHMAC meeting, the committee revised the Antidepressant Medications – Safe Use for All Ages criteria to reflect Spravato® labeling updates.

- i. Prior Authorization Criteria
- ii. \*Public Comment
- iii. Board Discussion

#### **3. Antipsychotic Medications – Safe Use for All Ages**

At the May 2021 MHMAC meeting, the committee revised the Antipsychotic Medications – Safe Use for All Ages criteria to include step therapy requirements for Secuado®.

- i. Prior Authorization Criteria
- ii. \*Public Comment
- iii. Board Discussion

### **B. Revised Prior Authorization (PA) Criteria**

#### **1. Crohn's Disease Agents**

This revision updates requirements for renewal prior authorization requests. It also updates requirements for Tysabri®.

- i. Revised PA Criteria
- ii. \*Public Comment
- iii. Board Discussion

#### **2. Oncology Agents**

This revision includes the addition of several drugs to the list of agents requiring prior authorization.

- i. Revised PA Criteria
- ii. \*Public Comment
- iii. Board Discussion

#### **3. Oncology – Auxiliary Treatment Agents**

This revision includes the addition of several drugs and consolidation of existing criteria (Anti-emetics: Neurokinin 1 (NK-1) Antagonists/NK-1 Antagonist Combinations).

- i. Revised PA Criteria
- ii. \*Public Comment
- iii. Board Discussion

**4. Migraine Prophylaxis Agents**

This revision includes the addition of Nurtec® ODT and adds step therapy.

- i. Revised PA Criteria
- ii. \*Public Comment
- iii. Board Discussion

**5. Weight Loss Agents**

This revision includes addition of Wegovy™ and revises the initial and renewal criteria for all agents.

- i. Revised PA Criteria
- ii. \*Public Comment
- iii. Board Discussion

**6. Ulcerative Colitis (UC) Agents**

This revision includes addition of Zeposia® to the list of agents requiring prior authorization and includes dosing information and renewal criteria.

- i. Revised PA Criteria
- ii. \*Public Comment
- iii. Board Discussion

**7. Minimum Requirements Prior Authorization**

This revision reflects an update to the age indication for Trikafta® use.

- i. Revised PA Criteria
- ii. \*Public Comment
- iii. Board Discussion

**8. Opioid Products Indicated for Pain Management**

This revision includes the addition of Qdolo™ and finalization of a minor clarification regarding approval duration.

- i. Revised PA Criteria
- ii. \*Public Comment
- iii. Board Discussion

**9. Atopic Dermatitis Agents**

This revision includes updates to the initial and renewal criteria.

- i. Revised PA Criteria
- ii. \*Public Comment
- iii. Board Discussion

**IV. APPOINTMENT OF CHAIRPERSON AND INTERIM CHAIRPERSON**

**V. ADJOURN**

**The next DUR Board meeting is scheduled for October 20, 2021.**

\*Public comment is limited to five minutes per product; additional time will be allowed at the DUR Board's discretion.

**\*\*THIS AGENDA IS SUBJECT TO CHANGE\*\***